<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01020630</url>
  </required_header>
  <id_info>
    <org_study_id>2009-02-SUN-Case</org_study_id>
    <nct_id>NCT01020630</nct_id>
  </id_info>
  <brief_title>Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI</brief_title>
  <acronym>SUN-CASE</acronym>
  <official_title>A Randomized, Placebo-controlled Phase II Trial Investigating SUNITINIB Versus Placebo in Patients With Chemorefractory Advanced Adenocarcinoma of the Stomach or Lower Esophagus Treated With Chemotherapy FOLFIRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PD Dr Markus Möhler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will be conducted to evaluate the efficacy, safety and tolerability of SUNITINIB&#xD;
      as add-on therapy with a widely used second-line palliative FOLFIRI chemotherapy in patients&#xD;
      with chemo-refractory advanced or metastatic adenocarcinoma of stomach or lower esophagus&#xD;
      (mGC).&#xD;
&#xD;
      There is a clear scientific rationale for the use of Sunitinib to treat patients with mGC.&#xD;
      Despite recent therapeutic advances, the median overall survival (OS) in patients with mG is&#xD;
      still ≤ 12 months. Therefore, newer agents with novel mechanisms of action are desperately&#xD;
      needed for treatment of these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In parallel to the efforts in front-line therapy, second-line protocols like irinotecan-based&#xD;
      regimens have been established in clinical trials for those patients. As many patients are&#xD;
      still in good performance status and present with low tumor burden after failure of&#xD;
      first-line chemotherapy, they clearly benefit from second-line treatment.&#xD;
&#xD;
      Sunitinib inhibits the receptor tyrosine kinases (RTKs) involved in tumor proliferation and&#xD;
      angiogenesis, specifically the VEGFR, PDGFR, KIT, FLT-3, and RET. The VEGF pathway has been&#xD;
      shown to be a significant factor in metastatic gastric cancer.&#xD;
&#xD;
      The safety and efficacy of Sunitinib as single agent for the treatment of mGC has been&#xD;
      determined and support the proposed clinical study with FOLFIRI in combination with Sunitinib&#xD;
      in the treatment of patients with mGC.&#xD;
&#xD;
      Patients included in this trial suffer from advanced or metastatic adenocarcinoma of stomach&#xD;
      or lower esophagus. They have failed to respond at least to one standard palliative&#xD;
      first-line therapy (based on docetaxel and/or cisplatin plus 5-FU). Irinotecan/FA/5-FU can be&#xD;
      determined as one established second-line treatment to be available for these patients.&#xD;
&#xD;
      Taken together, treatment of those patients with Sunitinib combined with standard&#xD;
      chemotherapy FOLFIRI offers the chance to benefit from a new innovative therapy with&#xD;
      acceptable side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the Progression-free survival (PFS) according to RECIST V1.1.</measure>
    <time_frame>Average time period: up to one year (participants are followed until progression or death)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (CR + PR) according to RECIST</measure>
    <time_frame>Average time period: up to one year (participants are followed until progression or death)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mg (2 capsules of 12.5 mg) for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 capsules for oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>Sunitinib will be orally administered at 25 mg once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.</description>
    <arm_group_label>Sunitinib</arm_group_label>
    <other_name>Sutent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be orally administered once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated informed consent before the start of specific protocol procedures&#xD;
&#xD;
          -  Histological proven gastric adenocarcinoma including adenocarcinoma of the&#xD;
             esophagogastric junction or lower esophagus&#xD;
&#xD;
          -  Failure of any prior chemotherapy (docetaxel and/or platinum-based chemotherapy); but&#xD;
             patient has not previously received FOLFIRI treatment&#xD;
&#xD;
          -  Measurable metastatic disease according to the RECIST criteria patients aged 18 years&#xD;
             and older&#xD;
&#xD;
          -  karnofsky index 100 - 70 %&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  Adequate hematological, hepatic and renal functions&#xD;
&#xD;
          -  At least 3 weeks from previous docetaxel- and/or platinum-based chemotherapy&#xD;
&#xD;
          -  Recovery from hematological side effects (CTC grade &lt;1) and non-hematological side&#xD;
             effects (CTC grade=&lt;1) of any prior therapy (except oxaliplatine induced neuropathy&#xD;
             CTC grade =&lt;2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of another primary malignancy &gt;3 years, with the exception of non-melanoma&#xD;
             skin cancer and in situ carcinoma of the uterine cervix&#xD;
&#xD;
          -  Any prior palliative radiotherapy of the target lesions&#xD;
&#xD;
          -  Concurrent treatment with any other medicinal anti-cancer therapy&#xD;
&#xD;
          -  Prior treatment with a VEGF, VEGFR or RTK inhibitor, or prior enrolment on this study&#xD;
&#xD;
          -  Known allergic/hypersensitivity reaction to any of the components of the treatment&#xD;
&#xD;
          -  Treatment with potent CYP3A4 inhibitor within 7 days of Sunitinib/placebo dosing or&#xD;
             with potent CYP3A4 inducer within 12 days of Sunitinib/placebo dosing&#xD;
&#xD;
          -  Other serious illness or medical conditions within the last 12 months prior to study&#xD;
             drug administration: Unstable cardiac disease despite treatment; myocardial infarction&#xD;
             within 12 months prior to study entry; congestive heart failure NYHA grade 3 and 4;&#xD;
             Hypertension that cannot be controlled by medication ; ongoing cardiac dysrhythmias of&#xD;
             NCI CTCAE grade &gt;2, atrial fibrillation of any grade, or QTc interval &gt;450 msec for&#xD;
             males or &gt;470 msec for females; History of significant neurologic or psychiatric&#xD;
             disorders including dementia or seizures; Active uncontrolled infection; History of&#xD;
             clinically significant bleeding within the past 6 months, including hemoptysis or&#xD;
             haematuria, or underlying coagulopathy; Active disseminated intravascular coagulation;&#xD;
             Cerebrovascular accident including transient ischemic attack; Pulmonary embolus; Bowel&#xD;
             obstruction or chronic diarrhoea, history or presence of inflammatory enteropathy or&#xD;
             extensive intestinal resection; History of abdominal fistula, gastrointestinal&#xD;
             perforation, or intra-abdominal abscess within 6 months prior to study enrolment,&#xD;
             unless affected area has been removed surgically&#xD;
&#xD;
          -  Known deficit in DPD&#xD;
&#xD;
          -  Hypercalcemia not controlled by bisphosphonates&#xD;
&#xD;
          -  Contraindications to the use of atropine&#xD;
&#xD;
          -  Pregnant or lactating women; female patients who are pregnant or lactating or men and&#xD;
             women of reproductive potential not willing or not able to employ an effective method&#xD;
             of birth control/contraception to prevent pregnancy during treatment and for 3 months&#xD;
             after discontinuing study treatment&#xD;
&#xD;
          -  Known drug abuse/alcohol abuse&#xD;
&#xD;
          -  Current, recent, or planned participation in an experimental treatment drug study&#xD;
             other than this protocol&#xD;
&#xD;
          -  Major surgical procedure, open biopsy or significant traumatic injury within 4 weeks&#xD;
             before starting treatment; anticipation of need for major surgical procedure (e.g.&#xD;
             impending bowel obstruction) during the course of the study&#xD;
&#xD;
          -  History of other medical or psychiatric condition, metabolic dysfunction, physical&#xD;
             examination finding, or clinical laboratory finding giving reasonable suspicion of a&#xD;
             disease or condition that contraindicates the use of an investigational drug or that&#xD;
             might affect the interpretation of the results of the study or render the patient at&#xD;
             high risk from treatment complications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Moehler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johannes Gutenberg University Mainz, 1. Med. Klinik</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz, 1. Med. Klinik</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gesundheitszentrum St. Marien</name>
      <address>
        <city>Amberg</city>
        <zip>92224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Berlin-Buch</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Berlin Charite</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Bielefeld</name>
      <address>
        <city>Bielefeld</city>
        <zip>33611</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen-Mitte</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-Universität Halle-Wittenberg</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ für Innere Medizin in Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigsburg Medizinische Klinik I</name>
      <address>
        <city>Ludwigsburg</city>
        <zip>71640</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technische Universität München</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Rostock Klinik für Innere Medizin</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leopoldina-Krankenhaus der Stadt Schweinfurt gGmbH</name>
      <address>
        <city>Schweinfurt</city>
        <zip>97422</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Weiden</name>
      <address>
        <city>Weiden</city>
        <zip>92637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>November 23, 2009</study_first_submitted>
  <study_first_submitted_qc>November 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <last_update_submitted>May 13, 2014</last_update_submitted>
  <last_update_submitted_qc>May 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>PD Dr Markus Möhler</investigator_full_name>
    <investigator_title>PD Dr.</investigator_title>
  </responsible_party>
  <keyword>adenocarcinoma of stomach</keyword>
  <keyword>adenocarcinoma of lower oesophagus</keyword>
  <keyword>sunitinib</keyword>
  <keyword>FOLFIRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 9, 2018</submitted>
    <returned>January 24, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

